In a significant development in the fight against dengue fever, Island Pharmaceuticals Ltd (ASX: ILA), a leading Australian antiviral drug development company, has announced the successful completion of dosing in its ISLA-101 Single Ascending Dose study. This marks a pivotal step in the company’s efforts to repurpose ISLA-101 for the prevention and treatment of dengue […]
Australia-based Island Pharmaceuticals Ltd (ASX: ILA) has achieved a significant milestone in its quest to combat mosquito-borne diseases, particularly dengue. The company announced the successful dosing of all eight subjects in the second cohort of its ISLA-101 Single Ascending Dose (SAD) study. This development marks a crucial step in repurposing ISLA-101 for the prevention and […]
Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA), has reached a milestone with the commencement of its Single Ascending Dose (SAD) study for ISLA-101. This well-known drug candidate, repurposed for the prevention and treatment of dengue and other mosquito-borne diseases, represents a major advance in the field. The SAD study, conducted at Scientia […]